We can have affordable medicines for all our health needs.
We don’t…because the current biotech/pharmaceutical industry is optimized to create wealth from medical products, rather than using wealth to create more affordable medicines.
Our name, The 90-10 Institute, says it all:
Only ten percent of the 10,000 defined diseases are adequately addressed via diagnosis, prevention or treatment: those that garner high profitability.
Each of us knows at least one person who has/d a serious condition or disease for which there was inadequate diagnosis or treatment
AND/OR
has confronted unaffordable costs for their diagnosis and care.
That’s because only 10% of the 10,000 defined diseases are adequately addressed via diagnosis, prevention or treatment: those addressed by medicines that garner high profitability.
Even though we have a vast reservoir of science to address the remaining 90%
We see the root cause:
the high cost of capital and the business practices to maximize profitability rather than maximizing health impact.
A New Era in Biotech
Our Mission: Create an industry that is financially viable while developing products that serve the 90 percent currently in need, at a cost that is affordable for ALL
We Envision Biotech Industry V2.0
Where We Are
Where We Need to Go
We Are Redesigning the BioTech Industry
At the 90-10 Institute…
We create BLUEPRINTS (models) for financing that balance medical impact with financial returns
AND
We cultivate an ecosystem of companies, investors, payers, and government that prioritizes health creation over wealth creation
SO THAT
We will have a financially viable industry that will produce medical products to serve today’s 90 percent of unmet needs at a cost that is affordable
FOR ALL
Together, we can chart a new course for how we do the business of biotech and pharmaceuticals.
90-10 Principles of Good Business in Medicine
Join us as we continue to pave the way for change, embracing a future where health is not a luxury but a universal right. The 90-10 Institute is more than a beacon; it's a resolute force driving the genetics and biotech revolution towards a regenerative and ethical future.
We know there are many out there – scientists, financial experts, engineers, entrepreneurs – who are already striving to implement our principles of good business in medicine.
